EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transplantation for Primary Sclerosing Cholangitis: Outcomes and Recurrence

Fuat H Saner iD, Alexandra Frey iD, Björn-Ole Stüben, Dieter P Hoyer, Katharina Willuweit, Martina Daniel, Jassin Rashidi-Alavieh iD, Jurgen W Treckmann, Hartmut H Schmidt

Journal of Clinical Medicine · 11.05.2023 · 12 (10) · 3405

DOI: 10.3390/jcm12103405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.05.2023. Verfasst von Fuat H Saner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General- and Visceral- and Transplant Surgery, Essen University Medical Center, 45147 Essen, Germany. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary sclerosing cholangitis (PSC) is characterized by inflammation of the whole bile duct system. Liver transplantation is only approved as a curative treatment when it comes to end-stage liver disease. The aim of our study was to assess morbidity, survival rates and PSC recurrence and the impact of donor characteristics in long-term follow-up. This was an IRB-approved retrospective study. A total of 82 patients were identified who were transplanted between January 2010 and December 2021 for PSC. Among these patients, 76 adult liver transplant PSC patients and their corresponding donors were analyzed. Three pediatric cases and three adult patients with a follow-up within 10 years (15 vs. 22, p = 0.004). Most patients (65%) passed in the first year following transplantation, with primary non-function (PNF), sepsis and arterial thrombosis being the most common causes of death. Donor characteristics did not affect patient survival. Patients with PSC show excellent 10-year survival rates. While the lab-MELD score significantly affected long term outcomes, donor characteristics did not affect survival rates.

Schlagwörter

Stichwörter der Autor:innen

cholestatic liver diseasecirrhosisdisease recurrenceimmunosuppressionliver transplantation

Autor:innen und Institutionen

  • Department of General- and Visceral- and Transplant Surgery, Essen University Medical Center, 45147 Essen, Germany.
  • Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
  • Department of Gastroenterology, Hepatology and Transplantation Medicine, Essen University Medical Center, 45147 Essen, Germany.

ORCID-Profile: Fuat H Saner, Alexandra Frey, Jassin Rashidi-Alavieh

Zitieren

APA

Saner, F. H., Frey, A., Stüben, B. O., Hoyer, D. P., Willuweit, K., Daniel, M., Rashidi-Alavieh, J., Treckmann, J. W., & Schmidt, H. H. (2023). Transplantation for Primary Sclerosing Cholangitis: Outcomes and Recurrence. Journal of Clinical Medicine, 12(10), 3405. https://doi.org/10.3390/jcm12103405

Vancouver

Saner FH, Frey A, Stüben BO, Hoyer DP, Willuweit K, Daniel M, et al. Transplantation for Primary Sclerosing Cholangitis: Outcomes and Recurrence. Journal of Clinical Medicine. 2023;12(10):3405. doi:10.3390/jcm12103405

BibTeX
@article{Saner2023,
  author = {Saner, Fuat H and Frey, Alexandra and Stüben, Björn-Ole and Hoyer, Dieter P and Willuweit, Katharina and Daniel, Martina and Rashidi-Alavieh, Jassin and Treckmann, Jurgen W and Schmidt, Hartmut H},
  title = {Transplantation for Primary Sclerosing Cholangitis: Outcomes and Recurrence},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {10},
  pages = {3405},
  doi = {10.3390/jcm12103405}
}
Kostenlos starten →